| abstract |
Provided herein are immunomodulatory polypeptides comprising a first subunit and a second subunit of a cytokine or chemokine linked by a linker region comprising a targeting moiety that binds to a target molecule. In some aspects, the present disclosure further relates to engineered cells and compositions comprising immunomodulatory polypeptides and methods of administering the same to a subject. In some embodiments, cells (eg, T cells) engineered to contain an immunomodulatory polypeptide further contain a genetically engineered antigen receptor, such as a chimeric antigen receptor (CAR), that specifically binds to the antigen. In some embodiments, the polypeptides, engineered cells, and methods of the polypeptides, engineered cells, and methods are immunogenic, eg, by reducing the adverse effects of cytokine or chemokine therapy or increasing the activity, efficacy, and/or persistence of adoptive cell therapy, or reducing its immunogenicity. A characteristic provides improvement in the treatment of a disease or disorder. |